Korean J Fam Pract 2019; 9(5): 471-474  https://doi.org/10.21215/kjfp.2019.9.5.471
A Case Report of Gynecomastia Due to Rosuvastatin
Joon Hoon Jeong1, Yun Seong Kim2, Sang Kwon Lee3,*
1Department of Internal Medicine, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 3Department of Thoracic Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
Sang Kwon Lee
Tel: +82-55-360-2127, Fax: +82-55-360-2157
E-mail: lsgwon@gmail.com
ORCID: http://orcid.org/0000-0003-4723-566X
Received: May 14, 2018; Revised: August 10, 2018; Accepted: November 1, 2018; Published online: October 20, 2019.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gynecomastia is a common benign disease characterized by the progressive enlargement of the glandular tissue of the male breast due to an imbalance between the levels of estrogen and androgen in the blood. The etiology may vary and may be physiological, pharmacological, pathological, or even idiopathic. Among men, drug-induced gynecomastia may account for 10% to 20% of cases. The literature contains six case reports of rosuvastatin-induced gynecomastia. Withdrawal of statin or switching to a less potent statin can lead to symptom improvement and avoidance of unnecessary tests and patient anxiety. A 62-year-old male patient developed unilateral gynecomastia after 13 months of rosuvastatin therapy. After switching to a different statin (pravastatin), his symptoms improved within 2 months. Thus, clinicians should be aware of the possibility of occurrence of gynecomastia when statins are prescribed.
Keywords: Gynecomastia; Drug-Related Side Effects and Adverse Reactions; Rosuvastatin Calcium
  1. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357: 1229-37.
    Pubmed CrossRef
  2. Neuman JF. Evaluation and treatment of gynecomastia. Am Fam Physician 1997; 55: 1835-44, 1849-50.
  3. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy 2012; 32: 1123-40.
    Pubmed CrossRef
  4. Aerts J, Karmochkine M, Raguin G. [Gynecomastia due to pravastatin]. Presse Med 1999; 28: 787. French.
  5. Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 2006; 26: 1165-8.
    Pubmed CrossRef
  6. Oteri A, Catania MA, Travaglini R, Russo A, Giustini SE, Caputi AP, et al. Gynecomastia possibly induced by rosuvastatin. Pharmacotherapy 2008; 28: 549-51.
    Pubmed CrossRef
  7. Picolos MK, Zeniou V, Michalis A. Rosuvastatin-induced gynaecomastia. Clin Endocrinol (Oxf) 2010; 73: 421-2.
    Pubmed CrossRef
  8. Roberto G, Biagi C, Montanaro N, Koci A, Moretti U, Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol 2012; 68: 1007-11.
    Pubmed CrossRef
  9. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol 2015; 71: 569-78.
    Pubmed KoreaMed CrossRef
  10. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49: 1234-8.
    Pubmed CrossRef
  11. Santini SA, Carrozza C, Lulli P, Zuppi C, CarloTonolo G, Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 2003; 10: 160-4.
    Pubmed CrossRef
  12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
    Pubmed CrossRef

This Article

Author ORCID Information

Social Network Service